Overcoming Treatment Toxicity through Sequential Therapy
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Cell Biology,Oncology
Reference10 articles.
1. Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma;Derenzini;Oncotarget,2015
2. Exploiting replicative stress to treat cancer;Dobbelstein;Nat. Rev. Drug Discov.,2015
3. Sequential therapy with PARP and WEE1 inhibitors minimizes toxicity while maintaining efficacy;Fang;Cancer Cell,2019
4. Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition;Haynes;Cancer Treat. Rev.,2018
5. The combination of the PARP inhibitor olaparib and the WEE1 inhibitor AZD1775 as a new therapeutic option for small cell lung cancer;Lallo;Clin. Cancer Res.,2018
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Nab -Paclitaxel plus Gemcitabine and FOLFOX in Metastatic Pancreatic Cancer;NEJM Evidence;2024-01-23
2. Key Proteins of Replication Stress Response and Cell Cycle Control as Cancer Therapy Targets;International Journal of Molecular Sciences;2024-01-19
3. Perspectives in ROS/Redox Regulation Cancer Therapy;Redox Regulation and Therapeutic Approaches in Cancer;2023
4. Harnessing DNA Double-Strand Break Repair for Cancer Treatment;Frontiers in Oncology;2019-12-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3